

ASSIGNMENT

We, the undersigned,

HA, Songyi; 107-902, 17, Suji-ro, Suji-gu
Yongin-si Gyeonggi-do 16863 (KR)

KIM, Gyoungwon; 18, Dongbaek 3-ro
60beon-gil, Giheung-gu Yongin-si
Gyeonggi-do 17009 (KR)

KIM, Gwanyoung; 201-3304, 40-18, Gogi-ro
45beon-gil, Suji-gu Yongin-si Gyeonggi-do
16824 (KR)

CHO, Sangeun; 440-2102, 87, Jukjeon-ro,
Suji-gu Yongin-si Gyeonggi-do 16899 (KR)

HWANG, On; 305-102, 1, Segwon-ro,
Gwonseon-gu Suwon-si Gyeonggi-do 16593
(KR)

PARK, Minhyung; 303ho, 8, Jeongjo-ro
535beon-gil, Gwonseon-gu Suwon-si
Gyeonggi-do 16587 (KR)

LEE, Seoyeo; 703ho, 14-2, Sinwon-ro
294beon-gil, Yeongtong-gu Suwon-si
Gyeonggi-do 16675 (KR)

LEE, Heewon; 116-203, 49, Yeonwon-ro,
Giheung-gu Yongin-si Gyeonggi-do 16908
(KR)

YOUN, Seungbin; 5202-2003, 65, Edu town-
ro, Yeongtong-gu Suwon-si Gyeonggi-do
16509 (KR),

which here and after is referred as the
ASSIGNOR,

By these presents declare under oath to be
the solo and true inventor/s of the invention
entitled: "PHARMACEUTICAL
COMPOSITION COMPRISING
ENAVOGLIFLOZIN", identified by
international application number
PCT/KR2022/014640

And,

DAEWOONG PHARMACEUTICAL CO.,
LTD., a corporation organized and existing
under the law of South Korea, having its
domiciled in 35-14, Jeyakgongdan 4-gil
Hyangnam-eup, Hwaseong-si Gyeonggi-do
18623, (KR) and represented by (individual's
name) Jyoung Kim acting a his
(her) (job title) IP team manager,
which here and after is named as
ASSIGNEE,

CESION

Nosotros, abajo firmando/s (Nombre del
inventor) _____, quien en
adelante será el CEDENTE,

HA, Songyi; 107-902, 17, Suji-ro, Suji-gu
Yongin-si Gyeonggi-do 16863 (KR)

KIM, Gyoungwon; 18, Dongbaek 3-ro
60beon-gil, Giheung-gu Yongin-si
Gyeonggi-do 17009 (KR)

KIM, Gwanyoung; 201-3304, 40-18, Gogi-ro
45beon-gil, Suji-gu Yongin-si Gyeonggi-do
16824 (KR)

CHO, Sangeun; 440-2102, 87, Jukjeon-ro,
Suji-gu Yongin-si Gyeonggi-do 16899 (KR)

HWANG, On; 305-102, 1, Segwon-ro,
Gwonseon-gu Suwon-si Gyeonggi-do 16593
(KR)

PARK, Minhyung; 303ho, 8, Jeongjo-ro
535beon-gil, Gwonseon-gu Suwon-si
Gyeonggi-do 16587 (KR)

LEE, Seoyeo; 703ho, 14-2, Sinwon-ro
294beon-gil, Yeongtong-gu Suwon-si
Gyeonggi-do 16675 (KR)

LEE, Heewon; 116-203, 49, Yeonwon-ro,
Giheung-gu Yongin-si Gyeonggi-do 16908
(KR)

YOUN, Seungbin; 5202-2003, 65, Edu town-
ro, Yeongtong-gu Suwon-si Gyeonggi-do
16509 (KR),

Por el presente documento declaramos bajo
juramento ser el/los único/s y verdadero/s
inventor/es de la invención titulada:
"COMPOSICIÓN FARMACÉUTICA QUE
COMPRENDE ENAVOGLIFLOZINA",
identificada mediante la solicitud
internacional número PCT/KR2022/014640

Y,

DAEWOONG PHARMACEUTICAL CO.,
LTD., una sociedad debidamente
constituida y existente bajo las leyes de
Corea del Sur, con domicilio en 35-14,
Jeyakgongdan 4-gil Hyangnam-eup,
Hwaseong-si Gyeonggi-do 18623, (KR) y
representada por (nombre) Jyoung Kim
—quien actúa como (título) IP team manager—
_____, quien en adelante será el
CESIONARIO,

Both, ASSIGNOR and ASSIGNEE have agreed the following:


To ASSIGN from the ASIGNOR to the ASSIGNEE the Industrial Property Rights related to the patent application entitled "PHARMACEUTICAL COMPOSITION COMPRISING ENAVOGLIFLOZIN".

Given on Feb. 26, 2024 in Seoul


ASSIGNER
HA, Songyi


ASSIGNER
KIM, Gyoungwon


ASSIGNER
KIM, Gwanyoung


ASSIGNER
CHO, Sangeun


ASSIGNER
HWANG, On


ASSIGNER
PARK, Minhyung


ASSIGNER
LEE, Seoyeo


ASSIGNER
LEE, Heewon


ASSIGNER
YOUN, Seungbin


ASSIGNEE
DAEWOONG PHARMACEUTICAL CO., LTD.

Ambos, CEDENTE y CESIONARIO han acordado lo siguiente:

CEDER del CEDENTE al CESIONARIO los derechos de propiedad Industrial relativos a la solicitud de patente titulada "COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE ENAVOGLIFLOZINA".

Dado en Feb. 26, 2024 el Seoul


CEDENTE
HA, Songyi


CEDENTE
KIM, Gyoungwon


CEDENTE
KIM, Gwanyoung


CEDENTE
CHO, Sangeun


CEDENTE
HWANG, On


CEDENTE
PARK, Minhyung


CEDENTE
LEE, Seoyeo


CEDENTE
LEE, Heewon


CEDENTE
YOUN, Seungbin


CESIONARIO
DAEWOONG PHARMACEUTICAL CO., LTD.